Recon Regulatory ZKR Orthopedics announces FDA Breakthrough Device designation for the LIFT Implant Technology byJosh SandbergOctober 10, 2023
Biologics Regulatory U.S. FDA Grants Lipogems® Second IDE Approval For A Clinical Trial On The Treatment For Knee OA byJosh SandbergOctober 4, 2023
Recon AAOS Updates Clinical Practice Guideline for Surgical Management of Osteoarthritis of the Knees byJosh SandbergJanuary 10, 2023
Sports Medicine Top Stories Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study byJosh SandbergSeptember 23, 2022
Financial Sports Medicine Moximed Raises $40 Million to Advance World’s First Implantable Shock Absorber for Knee Osteoarthritis byJosh SandbergAugust 16, 2022
Biologics Extremities Regulatory Lipogems® Receives IDE Approval From The U.S. FDA To Begin A Pivotal Clinical Study On The Safety And Effectiveness Of The Lipogems System For The Treatment of Knee Osteoarthritis byChris StewartJune 10, 2022
Biologics Regulatory First Subjects Randomized and Dosed in the U.S. under Phase III Pivotal Trial for the Treatment of Pain Associated with Knee OA byChris StewartMay 4, 2022
Extremities Recon Top Stories HSS Study Tackles Concomitant Limb Deformity, End-Stage Ankle OA byJosh SandbergApril 7, 2021
Recon New Invention Stops or Delays the Progression of Osteoarthritis of the Knee byChris StewartApril 1, 2021
Extremities Ensemble Orthopedics Announces Successful First Implantation Of Its Pyrocarbon Interpositional CMC byChris StewartMarch 25, 2021
